Growing evidence suggests that dipeptidyl peptidase 4 (DPP‐4) inhibitors, beyond their role in improving glycaemic control, are helpful in ameliorating endothelial dysfunction in humans and animal models of T2DM.6, 7, 8 A recent meta‐analysis supports that DPP4 inhibitors could reduce the risk of adverse cardiovascular events and are safe from a cardiovascular standpoint in patients with T2DM.9 The mechanisms of DPP4 inhibitors in this setting are highly associated with decreased inflammation and NADPH oxidase‐related oxidative stress.8, 10. The gene discussed is DPP4; the disease is type 2 diabetes mellitus.